Cryptococcosis Market Report 2026

Cryptococcosis Market Overview

• Cryptococcosis market size has reached to $7.07 billion in 2025 • Expected to grow to $10.8 billion in 2030 at a compound annual growth rate (CAGR) of 8.8% • Growth Driver: Rising Incidence Of Respiratory Infections Fueling The Growth Of The Cryptococcosis Market Due To Increasing Susceptibility To Opportunistic Diseases • Market Trend: Advancing Cryptococcosis Treatment Through Clinical Trials To Enhance Effectiveness And Safety • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cryptococcosis Market?

Cryptococcosis is a fungal infection caused by cryptococcus species such as Cryptococcus neoformans and Cryptococcus gattii, primarily affecting the lungs and central nervous system (CNS). It occurs in immunocompromised individuals, such as those with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS), organ transplant recipients, and patients on immunosuppressive therapy. This infection can lead to cryptococcal meningitis, which is life-threatening if untreated. The main treatment types of cryptococcosis are adjunctive therapies and antifungal drugs. Adjunctive therapies refer to additional treatments used alongside primary therapy to enhance effectiveness, improve patient outcomes, or manage side effects. The various diagnostic techniques include culture methods, microscopic examination, and molecular methods, to treat several types of infections including cerebral cryptococcosis and pulmonary cryptococcosis. The different end users encompass clinics, home healthcare, hospitals, and research institutes.

What Is The Cryptococcosis Market Growth Forecast?

The cryptococcosis market size is expected to see strong growth in the next few years. It will grow to $10.8 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to improved fungal diagnostics, expanding immunocompromised population, rising awareness of cryptococcal meningitis, development of safer antifungal regimens, improved access to healthcare services. Major trends in the forecast period include rising focus on early fungal infection diagnosis, increased use of combination antifungal therapy, growing monitoring of immunocompromised patients, expansion of hospital-based fungal care, improved access to molecular diagnostic methods.

Global Cryptococcosis Market Segmentation

1) By Treatment Type: Adjunctive Therapies, Antifungal Drugs 2) By Diagnostic Technique: Culture Methods, Microscopic Examination, Molecular Methods 3) By Infection Type: Cerebral Cryptococcosis, Pulmonary Cryptococcosis 4) By End User: Clinics, Home Healthcare, Hospitals, Research Institutes Subsegments: 1) By Adjunctive Therapies: Immunotherapy, Surgery, Supportive Care 2) By Antifungal Drugs: Amphotericin B, Fluconazole, Itraconazole, Voriconazole

What Are The Drivers Of The Cryptococcosis Market?

The rising incidence of respiratory infections is anticipated to propel the growth of the cryptococcosis market going forward. Respiratory infections are infections affecting the respiratory system, including the nose, throat, airways, and lungs, caused by viruses, bacteria, or fungi. The incidence of respiratory infections is increasing due to air pollution. Harmful pollutants such as smoke, dust, and chemicals damage lung function, increasing susceptibility to illnesses. A weakened immune system provides the ideal conditions for opportunistic diseases such as cryptococcosis to flourish. This fungal infection primarily affects the lungs and central nervous system, posing serious risks to immunocompromised individuals. For instance, in December 2024, according to the Australian Bureau of Statistics, an Australia-based government agency, influenza-related deaths rose in 2024, with 951 recorded deaths, compared to 427 deaths in 2022. Therefore, the rising incidence of respiratory infections is driving the growth of the cryptococcosis industry. The rising prevalence of human immunodeficiency virus (HIV) is expected to propel the growth of the cryptococcosis market going forward. Human immunodeficiency virus (HIV) is a virus that attacks the immune system, specifically targeting CD4 cells, making the body vulnerable to infections and diseases. The prevalence of HIV is increasing due to a lack of awareness and education about its transmission and prevention. This results in risky behaviors, late diagnosis, and a higher rate of unintentional virus spread. As HIV weakens the immune system, it makes individuals more vulnerable to opportunistic infections such as cryptococcosis. With more HIV cases, the risk of cryptococcal infections increases, leading to a higher demand for effective treatments, which drives market growth. For instance, in October 2024, according to the UK Health Security Agency, a UK-based government agency, there were 6,008 human immunodeficiency virus (HIV) diagnoses in 2023, an increase of 51% from 3,975 in 2022. Therefore, the rising prevalence of human immunodeficiency virus (HIV) is driving the growth of the cryptococcosis industry.

Key Players In The Global Cryptococcosis Market

Major companies operating in the cryptococcosis market are Pfizer Inc, Johnson & Johnson, Merck and Co Inc, Abbott Laboratories, Gilead Sciences Inc, Asahi Kasei Pharma Corporation, Viatris Inc, Astellas Pharma Inc, Bausch Health Companies Inc, Sun Pharmaceutical Industries Ltd, Cipla Limited, Dr Reddys Laboratories, Century Pharmaceuticals Ltd, Beijing Lunarsun Pharmaceutical Co Ltd, Matinas Biopharma Holdings Inc, LGM Pharma, Atom Pharma, Brundavan Laboratories Pvt Ltd, Amar Healthcare, Novartis AG, Sanofi SA, Bristol Myers Squibb, Teva Pharmaceutical Industries Ltd, Lupin Limited, Glenmark Pharmaceuticals Ltd

Global Cryptococcosis Market Trends and Insights

Major companies operating in the cryptococcosis market are actively engaged in clinical trials to develop safer and more effective antifungal treatments. Clinical trials help evaluate new therapies and improve treatment outcomes for patients with severe fungal infections. For instance, in August 2023, Matinas BioPharma Holdings Inc., a US-based clinical-stage biopharmaceutical company, announced promising results from the Phase II EnACT trial evaluating MAT2203 for the treatment of cryptococcal meningitis. MAT2203 is an oral lipid nanocrystal formulation of amphotericin B that targets fungal cell membranes, disrupting their structure and causing fungal cell death. The study demonstrated improved patient survival rates and a favorable safety profile, highlighting its potential as a groundbreaking treatment for cryptococcosis, including cryptococcal meningitis.

Regional Outlook

North America was the largest region in the cryptococcosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cryptococcosis Market?

The cryptococcosis market consists of revenues earned by entities by providing services such as diagnostic testing, antifungal treatment, hospital care, disease management, telemedicine consultations, research and development, clinical trials, patient monitoring, and epidemiological surveillance. The market value includes the value of related goods sold by the service provider or included within the service offering. The cryptococcosis market also includes sales of amphotericin B, flucytosine, fluconazole, and voriconazole. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cryptococcosis Market Report 2026?

The cryptococcosis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cryptococcosis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.